L
Lakshmi Nayak
Researcher at Harvard University
Publications - 132
Citations - 5754
Lakshmi Nayak is an academic researcher from Harvard University. The author has contributed to research in topics: Primary central nervous system lymphoma & Bevacizumab. The author has an hindex of 31, co-authored 116 publications receiving 4080 citations. Previous affiliations of Lakshmi Nayak include Cornell University & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Epidemiology of Brain Metastases
TL;DR: The incidence of brain metastases is increasing with the availability of improved imaging techniques which aid early diagnosis, and effective systemic treatment regimens which prolong life, thus allowing cancer to disseminate to the brain.
Journal ArticleDOI
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
Hideho Okada,Michael Weller,Raymond Y. Huang,Gaetano Finocchiaro,Mark R. Gilbert,Wolfgang Wick,Benjamin M. Ellingson,Naoya Hashimoto,Ian F. Pollack,Alba A. Brandes,Enrico Franceschi,Christel Herold-Mende,Lakshmi Nayak,Ashok Panigrahy,Whitney B. Pope,Robert M. Prins,John H. Sampson,Patrick Y. Wen,David A. Reardon +18 more
TL;DR: Immunotherapy Response Assessment for Neuro-Oncology (iRANO) criteria based on guidance for the determination of tumour progression outlined by the immune-related response criteria and the RANO working group are described.
Journal ArticleDOI
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
Nicholas Butowski,Howard Colman,John de Groot,Antonio Omuro,Lakshmi Nayak,Patrick Y. Wen,Timothy F. Cloughesy,Adhirai Marimuthu,Sam Haidar,Arie Perry,Jason T. Huse,Joanna J. Phillips,Brian L. West,K. B. Nolop,Henry H. Hsu,Keith L. Ligon,Annette M. Molinaro,Michael D. Prados +17 more
TL;DR: PLX3397 was well tolerated and readily crossed the blood-tumor barrier but showed no efficacy, and additional studies are ongoing, testing combination strategies and potential biomarkers to identify patients with greater likelihood of response.
Journal ArticleDOI
Mechanisms and therapeutic implications of hypermutation in gliomas.
Mehdi Touat,Mehdi Touat,Mehdi Touat,Yvonne Y. Li,Yvonne Y. Li,Adam Boynton,Adam Boynton,Liam F. Spurr,Liam F. Spurr,J. Bryan Iorgulescu,J. Bryan Iorgulescu,Craig L. Bohrson,Isidro Cortes-Ciriano,Cristina Birzu,Jack Geduldig,Kristine Pelton,Mary Jane Lim-Fat,Mary Jane Lim-Fat,Sangita Pal,Sangita Pal,Ruben Ferrer-Luna,Ruben Ferrer-Luna,Ruben Ferrer-Luna,Shakti H. Ramkissoon,Shakti H. Ramkissoon,Frank Dubois,Frank Dubois,Charlotte Bellamy,Naomi Currimjee,Juliana Bonardi,Kenin Qian,Patricia Ho,Seth Malinowski,Leon Taquet,Robert E. Jones,Aniket Shetty,Kin-Hoe Chow,Radwa Sharaf,Dean Pavlick,Lee A. Albacker,Nadia Younan,Capucine Baldini,Maite Verreault,Marine Giry,Erell Guillerm,Samy Ammari,Samy Ammari,Frédéric Beuvon,Karima Mokhtari,Agusti Alentorn,Caroline Dehais,Caroline Houillier,Florence Laigle-Donadey,Dimitri Psimaras,Eudocia Q. Lee,Eudocia Q. Lee,Lakshmi Nayak,Lakshmi Nayak,J Ricardo McFaline-Figueroa,J Ricardo McFaline-Figueroa,Alexandre Carpentier,Philippe Cornu,Laurent Capelle,Bertrand Mathon,Jill S. Barnholtz-Sloan,Arnab Chakravarti,Wenya Linda Bi,E. Antonio Chiocca,Katie Pricola Fehnel,Sanda Alexandrescu,Susan N. Chi,Susan N. Chi,Daphne A. Haas-Kogan,Tracy T. Batchelor,Tracy T. Batchelor,Garrett M. Frampton,Brian M. Alexander,Brian M. Alexander,Raymond Y. Huang,Azra H. Ligon,Florence Coulet,Jean-Yves Delattre,Jean-Yves Delattre,Khê Hoang-Xuan,David Meredith,David Meredith,Sandro Santagata,Alex Duval,Marc Sanson,Marc Sanson,Andrew D. Cherniack,Andrew D. Cherniack,Patrick Y. Wen,Patrick Y. Wen,David A. Reardon,Aurélien Marabelle,Peter J. Park,Ahmed Idbaih,Rameen Beroukhim,Rameen Beroukhim,Rameen Beroukhim,Pratiti Bandopadhayay,Pratiti Bandopadhayay,Pratiti Bandopadhayay,Franck Bielle,Keith L. Ligon +105 more
TL;DR: Results show that chemotherapy can drive the acquisition of hypermutated populations without promoting a response to PD-1 blockade and supports the diagnostic use of mutational burden and signatures in cancer.
Journal ArticleDOI
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
Lakshmi Nayak,Lakshmi Nayak,Fabio M. Iwamoto,Ann S. LaCasce,Ann S. LaCasce,Srinivasan Mukundan,Srinivasan Mukundan,Margaretha G.M. Roemer,Bjoern Chapuy,Philippe Armand,Philippe Armand,Scott J. Rodig,Scott J. Rodig,Margaret A. Shipp,Margaret A. Shipp +14 more
TL;DR: The data suggest that nivolumab is active in relapsed/refractory PCNSL and PTL and support further investigation of PD-1 blockade in these diseases.